Project profile — Support to COVID-19 therapeutics



Overview 

CA-3-P009758001
$15,000,000
WHO - World Health Organization (41143)
2021-03-30 - 2023-03-31
Closed
Global Affairs Canada
YFMInternaAssistPartnershp&Programing Br

Country / region 

• Africa, regional (20.00%)
• America, regional (20.00%)
• Asia, regional (20.00%)
• Oceania, regional (20.00%)
• Europe, regional (20.00%)

Sector 

• Basic Health: Infectious disease control (12250) (50.00%)
• Health: COVID-19 control (12264) (50.00%)

Policy marker 

• Gender equality (significant objective)

Description 

This project aims to advance equitable and affordable access to the most promising COVID-19 treatments in lower-income countries and lower-middle-income countries (LMICs). The project supports Unitaid in securing manufacturing capacity and supply for relevant treatments, including monoclonal antibodies, novel antivirals, and medical oxygen. This project contributes to the Access to COVID-19 Tools (ACT) -– Accelerator Therapeutics Partnership objectives. Project activities include: (1) increasing access to medical oxygen ; (2) improving supply security across sub-Saharan Africa through market interventions; and (3) piloting the introduction, feasibility and acceptability of innovations in at least 5 countries.

Expected results 

The expected outcomes of the project include: (1) increased capacity of oxygen produced and delivered to low- and lower-middle income countries; (2) an expanded portfolio of fit-for-purpose new therapeutics adapted for LMICs; and (3) ensured availability and affordability of therapeutics and a related package of care in low- and lower-middle income countries.

Results achieved 

N/A

Budget and spending 


Original budget $0
Planned disbursement $0
Transactions
Country percentages by sector
Type of finance Aid grant excluding debt reorganisation
Collaboration type Bilateral
Type of aid Contributions to specific-purpose programmes and funds managed by implementing partners
Date modified: